文献速递重症综合管理与镇静镇痛

氟哌啶醇与安慰剂治疗ICU患者谵妄的比较:AID-ICU试验的预设次要贝叶斯分析

Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial.
PubMed 文献 · Intensive Care Med · 2023-03-27
一句话结论AID-ICU预设贝叶斯分析显示,急性入ICU的成人谵妄患者使用氟哌啶醇相比安慰剂,主要和多数次要结局获益概率高、危害概率低。

AID-ICU试验是随机、盲法、安慰剂对照试验,纳入急性入ICU的成人谵妄患者,比较氟哌啶醇与安慰剂。本预设贝叶斯分析采用弱信息先验的校正贝叶斯线性与逻辑回归模型分析至第90天所有主要和次要结局,并做不同先验的敏感性分析。结果显示,至第90天存活且出院天数的均数差为2.9天(95%可信区间-1.1至6.9),任何获益概率92%、临床重要获益概率82%;死亡风险差为-6.8个百分点(95%可信区间-12.8至-0.8),任何获益概率99%、临床重要获益概率94%;严重不良反应校正风险差0.3个百分点(95%可信区间-1.3至1.9),无临床重要差异概率98%。敏感性分析结果一致,氟哌啶醇获益概率超过83%、危害概率低于17%。

要点

  • 至第90天存活且出院天数:氟哌啶醇较安慰剂均数差2.9天(95%可信区间-1.1至6.9),任何获益概率92%、临床重要获益82%。
  • 死亡风险差:氟哌啶醇较安慰剂-6.8个百分点(95%可信区间-12.8至-0.8),任何获益概率99%、临床重要获益94%。
  • 严重不良反应校正风险差:氟哌啶醇较安慰剂0.3个百分点(95%可信区间-1.3至1.9),无临床重要差异概率98%。
  • 不同先验的敏感性分析结果一致,氟哌啶醇获益概率超过83%、危害概率低于17%。

适用人群与场景

  • 急性入ICU的成人谵妄患者(AID-ICU试验纳入人群)

研究设计与关键结果

  • 研究设计:AID-ICU试验的预设次要贝叶斯分析,原试验为随机、盲法、安慰剂对照试验,比较氟哌啶醇与安慰剂。
  • 分析采用校正贝叶斯线性与逻辑回归模型、弱信息先验,分析至第90天所有主要和次要结局,并用其他先验做敏感性分析。
  • 主要结局(至第90天存活且出院天数):氟哌啶醇较安慰剂均数差2.9天(95%可信区间-1.1至6.9),任何获益概率92%、临床重要获益概率82%。
  • 死亡风险差:氟哌啶醇较安慰剂-6.8个百分点(95%可信区间-12.8至-0.8),任何获益概率99%、临床重要获益概率94%。
  • 严重不良反应校正风险差:氟哌啶醇较安慰剂0.3个百分点(95%可信区间-1.3至1.9),无临床重要差异概率98%。
  • 敏感性分析:使用不同先验的结果一致,氟哌啶醇获益概率超过83%、危害概率低于17%。

证据类型、等级与局限

  • 证据类型:随机、盲法、安慰剂对照试验(AID-ICU)的预设次要贝叶斯分析。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,在急性入ICU的成人谵妄患者中,与安慰剂相比,氟哌啶醇在主要和多数次要结局上获益概率高、危害概率低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The AID-ICU trial was a randomised, blinded, placebo-controlled trial investigating effects of haloperidol versus placebo in acutely admitted, adult patients admitted in intensive care unit (ICU) with delirium. This pre-planned Bayesian analysis facilitates probabilistic interpretation of the AID-ICU trial results.

METHODS: We used adjusted Bayesian linear and logistic regression models with weakly informative priors to analyse all primary and secondary outcomes reported up to day 90, and with sensitivity analyses using other priors. The probabilities for any benefit/harm, clinically important benefit/harm, and no clinically important differences with haloperidol treatment according to pre-defined thresholds are presented for all outcomes.

RESULTS: The mean difference for days alive and out of hospital to day 90 (primary outcome) was 2.9 days (95% credible interval (CrI) - 1.1 to 6.9) with probabilities of 92% for any benefit and 82% for clinically important benefit. The risk difference for mortality was - 6.8 percentage points (95% CrI - 12.8 to - 0.8) with probabilities of 99% for any benefit and 94% for clinically important benefit. The adjusted risk difference for serious adverse reactions was 0.3 percentage points (95% CrI - 1.3 to 1.9) with 98% probability of no clinically important difference. Results were consistent across sensitivity analyses using different priors, with more than 83% probability of benefit and less than 17% probability of harm with haloperidol treatment.

CONCLUSIONS: We found high probabilities of benefits and low probabilities of harm with haloperidol treatment compared with placebo in acutely admitted, adult ICU patients with delirium for the primary and most secondary outcomes.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Andersen-Ranberg NC, Poulsen LM, Perner A, et al. Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. Intensive Care Med. 2023. PMID: 36971791. doi:10.1007/s00134-023-07024-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。